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Acute genital vulvar ulcerations are non-sexually acquired
lesions characterized by sudden onset of a few genital ulcers,
presented typically in girls and young women. The terms
AGU or Lipsch€utz ulceration are used to describe ulcers asso-
ciated with an immunologic reaction to a distant source of
infection or inflammation.6 The most common triggering fac-
tors are infectious diseases, specially flu-like and mononucleo-
sis syndrome infections.5,7 In many cases, the patients present
also other symptoms, mainly oral aphthae, malaise, lym-
phadenopathy or fever,8 and concomitant cutaneous manifes-
tations such as erythema nodosum can also be observed.6
Therapies for AGU include anti-inflammatory drugs, topical
anaesthetics and corticosteroids. When a triggering infection
is documented, antimicrobial agents are also useful for the
management of the ulcerations. The lesions commonly resolve
within 3 weeks.
Some virus species have been well defined as triggering agents
of Lipsch€utz ulcers, specially Epstein–Barr virus. Although SARS
Coronavirus 2 has been associated with oral ulcers,9 we did not
find previous reports of coronavirus-related AGU in the English
literature. We report this case in order to describe a potential
reactive dermatologic manifestation of the COVID-19. More-
over, we propose that Lipsch€utz ulcers could be triggered by
SARS Coronavirus 2, comparably to other respiratory virus
infections.
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2019 patients: a report of six
cases with clinicopathologic
features and viral RNA in situ
hybridization
Dear Editor,
Novel coronavirus disease 2019 (COVID-19) caused by the sev-
ere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
was declared a global pandemic on March 2020.1 Recalcati et al.2
reported cutaneous manifestations in 20.4% of COVID-19
patients. We identified six patients (five female and one male)
with COVID-19-associated cutaneous manifestations in April
2020 on the inpatient dermatology consultation service. The
mean age was 51 years (range, 28–71 years). All patients pre-
sented with fever and upper respiratory symptoms. The median
latency before onset of the rash was 9 days (range, 2–21 days).
RNAscope ISH assay targeting the SARS-CoV-2 mRNA tran-
script for the spike protein (V-nCoV2019-S, ACD catalog
#848569), validated on positive controls from COVID-19
autopsy lung tissue, was negative in all skin biopsy specimens.
Three novel cutaneous patterns were identified: (i) COVID-19-
associated exfoliative shock syndrome in two patients presenting
with fever, hypotension and a diffuse exfoliative rash that spared
mucous membranes (Fig. 1a,b). Skin biopsies demonstrated a
subcorneal split with intracorneal neutrophils, parakeratosis and
scant dermal inflammation (Fig. 1c,d). Pancultures were nega-
tive for staphylococcal infection. Given the overlapping features
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of toxic shock syndrome (TSS) and staphylococcal scalded skin
syndrome (SSSS), the patients were diagnosed with COVID-19-
associated exfoliative shock syndrome. One patient expired, and
the second patient improved with linezolid. (ii) COVID-19-in-
duced rash and mucositis (CIRM) was diagnosed in one patient
who developed a Stevens–Johnson syndrome (SJS)-like eruption
in the absence of prior drug exposure. The SARS-CoV-2-positive
patient presented with fever and oral erosions. She then devel-
oped widespread dusky targetoid papules and bullae with exten-
sive denudation (Fig. 2a) and worsening mucous membranes
involvement. Skin biopsy demonstrated full-thickness epidermal
necrosis (Fig. 2b). (iii) COVID-19-associated calciphylaxis with
thrombotic vasculopathy was identified in a patient presenting
with painful retiform purpura consisting of angulated violaceous
plaques with necrotic centres on the bilateral legs (Fig. 2c). Skin
biopsy showed epidermal necrosis with vascular thrombi and
calcification of small- to medium-sized vessels (Fig. 2d). Labora-
tory workup was remarkable for elevated D-dimer and fibrino-
gen. Creatinine, calcium and phosphorus levels were normal.
We present three novel COVID-19-associated cutaneous
manifestations in hospitalized patients. Two patients presented
with a COVID19-associated exfoliative shock syndrome. Recent
reports describe a similar hyperinflammatory shock syndrome in
children with overlapping features of Kawasaki disease and TSS.3
Our patients also presented with fever, hypotension and an exfo-
liative skin eruption with overlapping features of TSS and SSSS.
No gastrointestinal symptoms were observed. Staphylococcus
aureus superinfection is a well-recognized event in the setting of
viral diseases due to upregulation of IFN-a.4 COVID-19 induces
a cytokine storm, raising the levels of proinflammatory cytokines
such as IFN-a,5 thus potentially increasing host susceptibility for
bacterial superinfection. It is unclear whether this presentation is
a direct consequence of COVID-19-induced multisystem inflam-
matory syndrome in predisposed patients or an undetected
staphylococcal superinfection. The second pattern identified was
CIRM, an eruption that mimics SJS. Exfoliative mucocutaneous
eruptions associated with infection are a well-recognized phe-
nomenon.6 CD8 cytotoxic T cells, together with the cytokine
storm occurring in the setting of COVID-19, may contribute to
this severe cutaneous reaction leading to necrosis of ker-
atinocytes. The histopathologic findings of CIRM are indistin-
guishable from SJS; however, the time course of events, careful
drug history and identification of concurrent infection can allow
for distinction. COVID-19-associated calciphylaxis with throm-
botic vasculopathy is the third pattern observed. The pathogene-
sis of nonuremic calciphylaxis is primarily related to a
(a) (b)
(c) (d)
Figure 1 Clinical and histopathologic features of patients with COVID-19-associated exfoliative shock syndrome. Patient 1: (a) Erythe-
matous plaques with superficial exfoliation on the abdomen. (b) Patient 2: Erythematous to dusky plaques with superficial exfoliation on
the trunk. Patient 1: (c) Haematoxylin and eosin stain of punch biopsy showing subcorneal split (**) with parakeratosis and intracorneal
neutrophils (original magnification 9100). Inset showing parakeratotic scale with neutrophilic fragments (original magnification 9200). (d)
Patient 2: Haematoxylin and eosin stain of punch biopsy showing subcorneal split (**) with parakeratosis and intracorneal neutrophils
(original magnification 9100). Inset showing scant superficial dermal neutrophilic infiltrate (original magnification 9200).
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hypercoagulable state and thrombotic vasculopathy.7 COVID-
19-associated coagulopathy with initial signs of increased D-
dimer and fibrinogen as seen in our patient is well-documented.8
The abrupt onset of calciphylaxis with thrombotic vasculopathy
and concomitant COVID-19 infection is suspect and suggests
that COVID-19 infection may increase susceptibility for nonure-
mic calciphylaxis. Finally, in two patients we observed COVID-
19-associated morbilliform exanthems that demonstrated a
superficial perivascular dermatitis on histopathology.
Viral mRNA was not detected using RNA ISH for SARS-CoV-
2, suggesting that cutaneous manifestations associated with
COVID-19 are secondary to dysregulation of the immune and
coagulation pathways rather than direct viral skin toxicity.
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SARS-CoV-2, skin lesions and
the need of a multidisciplinary
approach
Editor
COVID-19 is a disease caused by severe acute respiratory syn-
drome coronavirus 2 of the genus Betacoronavirus (SARS-CoV-
2). It was first described in Wuhan (China) on December 2019
and has spread to become a pandemic. Its clinical presentation is
mainly characterized by cough, fever and dyspnoea, although
many other symptoms have been described within its presenta-
tion pattern. In some cases, it causes an acute respiratory distress
that has lead to the death of thousands of people around the
world. Furthermore, different types of skin lesions have been
described during the infection period of illness.1 In this excep-
tional situation of global health emergency, physicians are
undertaking research work in order to achieve notions on the
aetiopathogenesis of these skin lesions. The first report of cuta-
neous manifestations described different forms of skin lesions
such as erythematous rash, urticaria and chickenpox-like vesi-
cles.2 Further studies have classified 5 different type of skin
lesions and associated them with patient demographics, timing
in relation to symptoms of the disease, severity and prognosis.1
Acro-ischaemic lesions have also been notified and attributed to
disseminated intravascular coagulation and to the expression of
secondary microthrombosis due to endothelial damage.3-5 How-
ever, to date, there is no clear understanding on whether the skin
lesions are secondary to the viral infection nor why there are dif-
ferent presentations of skin lesions for the same viral infection.
We present 4 patients with COVID-19, confirmed by positive
polymerase chain reaction, who were referred to our service due
to the appearance of skin lesions (Fig. 1). Two of them devel-
oped skin lesions during hospitalization whilst presenting respi-
ratory symptoms, and the other two developed skin lesions
many days after hospital discharge. Demographic data, descrip-
tion and histology of skin lesions, blood parameters, clinical
symptoms and drugs administered are shown in Table 1. The
algorithm of the spanish pharmacovigilance system (ASPS),
which evaluates the possible implication of a drug reaction as a
cause of the skin lesions,6 was also applied. The ASPS analyzes i)
the interval between drug administration and the apparition of
skin lesions, ii) the degree of knowledge of the relationship
between the drug and the effect described in literature, iii) the
evaluation of drug withdrawal, iv) the rechallenge effect and v)
alternative causes. Each item receives an individual subscore,
and a total sum ≥6 indicates a probable causality.6
As mentioned above, skin lesions appear to be a sign within
patients suffering from COVID-19. To date, no hypothesis has
been proposed to explain if the lesions (including the different
types) are attributable to the virus, to drug adverse reactions or
to any other clinical condition. Histopathological study alone
cannot conclude an aetiology, as it does not distinguish between
a possible viral exanthema and a toxicoderma (Fig. 1). In our
series, small enough to draw conclusions, we have found no dif-
ferences between the multiple types of skin lesions and analytical
or clinical features. Even in lesions with apparent vascular
involvement, which have been associated with alterations in
coagulation,3-5 the analytical parameters did not differ from
those with other types of skin lesions. Regarding drug involve-
ment, since all the patients were exposed to multiple drugs at the
same time, the ASPS was not able to differentiate the possibility
of drug implication nor the immune mechanisms involved.
Thus, further assays with selective (in vitro or in vivo) tests for
each drug seem necessary in order to completely rule out drug
involvement. In addition, since many patients worldwide are
being infected with SARS-Cov-2, and many of them present sim-
ilar medical history and receive the same treatments, it seems
necessary to investigate the existence of an individual predisposi-
tion that facilitates the development of skin lesions. For all these
reasons, in order to correctly study the aetiology of the skin
lesions, a multidisciplinary approach should be carried out.
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